Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk
Diabetes Care · 01.11.2023 · 46 (11) · 1978-1985
DOI: 10.2337/dc23-0805 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes Care, online erschienen am 27.09.2023. Verfasst von Deirdre K Tobias und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Coronary Disease. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NHGRI NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Clonal hematopoiesis of indeterminate potential (CHIP) is an aging-related accumulation of somatic mutations in hematopoietic stem cells, leading to clonal expansion. CHIP presence has been implicated in atherosclerotic coronary heart disease (CHD) and all-cause mortality, but its association with incident type 2 diabetes (T2D) is unknown. We hypothesized that CHIP is associated with elevated risk of T2D. RESEARCH DESIGN AND METHODS CHIP was derived from whole-genome sequencing of blood DNA in the National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine (TOPMed) prospective cohorts. We performed analysis for 17,637 participants from six cohorts, without prior T2D, cardiovascular disease, or cancer. We evaluated baseline CHIP versus no CHIP prevalence with incident T2D, including associations with DNMT3A, TET2, ASXL1, JAK2, and TP53 variants. We estimated multivariable-adjusted hazard ratios (HRs) and 95% CIs with adjustment for age, sex, BMI, smoking, alcohol, education, self-reported race/ethnicity, and combined cohorts’ estimates via fixed-effects meta-analysis. RESULTS Mean (SD) age was 63.4 (11.5) years, 76% were female, and CHIP prevalence was 6.0% (n = 1,055) at baseline. T2D was diagnosed in n = 2,467 over mean follow-up of 9.8 years. Participants with CHIP had 23% (CI 1.04, 1.45) higher risk of T2D than those with no CHIP. Specifically, higher risk was for TET2 (HR 1.48; CI 1.05, 2.08) and ASXL1 (HR 1.76; CI 1.03, 2.99) mutations; DNMT3A was nonsignificant (HR 1.15; CI 0.93, 1.43). Statistical power was limited for JAK2 and TP53 analyses. CONCLUSIONS CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Nutrition Department, Harvard T.H. Chan School of Public Health, Boston, MA.
- Broad Metabolism Program, Broad Institute of MIT and Harvard, Cambridge, MA.
- Harvard Medical School, Boston, MA.
- Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Boston, MA.
- Department of Epidemiology, Richard M. Fairbanks School of Public Health, Department of Medicine, School of Medicine, and Diabetes Translational Research Center, Indiana University, Indianapolis, IN.
ORCID-Profile: Deirdre K Tobias
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NHGRI NIH HHS
- WHI NIH HHS
- NCATS NIH HHS
- CSRD VA
- NIMHD NIH HHS
- NIEHS NIH HHS
Zitieren
APA
Tobias, D. K., Manning, A. K., Wessel, J., Raghavan, S., Westerman, K. E., Bick, A. G., Dicorpo, D., Whitsel, E. A., Collins, J., Correa, A., Cupples, L. A., Dupuis, J., Goodarzi, M. O., Guo, X., Howard, B., Lange, L. A., Liu, S., Raffield, L. M., Reiner, A. P., …, & TOPMed Diabetes Working Group and National Heart, Lung, and Blood Institute TOPMed Consortium (2023). Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk. Diabetes Care, 46(11), 1978-1985. https://doi.org/10.2337/dc23-0805
Vancouver
Tobias DK, Manning AK, Wessel J, Raghavan S, Westerman KE, Bick AG, et al. Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk. Diabetes Care. 2023;46(11):1978-1985. doi:10.2337/dc23-0805
BibTeX
@article{Tobias2023,
author = {Tobias, Deirdre K and Manning, Alisa K and Wessel, Jennifer and Raghavan, Sridharan and Westerman, Kenneth E and Bick, Alexander G and Dicorpo, Daniel and Whitsel, Eric A and Collins, Jason and Correa, Adolfo and Cupples, L Adrienne and Dupuis, Josée and Goodarzi, Mark O and Guo, Xiuqing and Howard, Barbara and Lange, Leslie A and Liu, Simin and Raffield, Laura M and Reiner, Alex P and Rich, Stephen S and Taylor, Kent D and Tinker, Lesley and Wilson, James G and Wu, Peitao and Carson, April P and Vasan, Ramachandran S and Fornage, Myriam and Psaty, Bruce M and Kooperberg, Charles and Rotter, Jerome I and Meigs, James and Manson, JoAnn E and TOPMed Diabetes Working Group and National Heart, Lung, and Blood Institute TOPMed Consortium, TOPMed Diabetes Working Group and National Heart, Lung, and Blood Institute TOPMed Consortium},
title = {Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {11},
pages = {1978--1985},
doi = {10.2337/dc23-0805}
}
EUVIMED